Royce & Associates LP Has $97.30 Million Position in Haemonetics Co. (NYSE:HAE)

Royce & Associates LP raised its position in Haemonetics Co. (NYSE:HAE - Free Report) by 2.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,210,546 shares of the medical instruments supplier's stock after buying an additional 30,868 shares during the period. Haemonetics accounts for 0.9% of Royce & Associates LP's investment portfolio, making the stock its 6th biggest holding. Royce & Associates LP owned 2.37% of Haemonetics worth $97,304,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the company. Capital Research Global Investors lifted its holdings in Haemonetics by 2.3% during the first quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier's stock worth $569,690,000 after acquiring an additional 151,183 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Haemonetics by 6.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier's stock worth $80,972,000 after purchasing an additional 57,665 shares during the period. Thrivent Financial for Lutherans boosted its holdings in shares of Haemonetics by 6,573.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier's stock worth $70,267,000 after buying an additional 836,623 shares during the last quarter. Boston Trust Walden Corp grew its position in Haemonetics by 13.8% during the third quarter. Boston Trust Walden Corp now owns 809,608 shares of the medical instruments supplier's stock valued at $65,076,000 after buying an additional 98,019 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in Haemonetics by 75.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier's stock worth $63,933,000 after buying an additional 343,214 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

Haemonetics Trading Down 1.7 %

Shares of Haemonetics stock traded down $1.53 during midday trading on Friday, reaching $89.22. 564,400 shares of the company's stock traded hands, compared to its average volume of 555,780. The company has a market cap of $4.48 billion, a PE ratio of 37.01, a price-to-earnings-growth ratio of 1.43 and a beta of 0.32. The stock has a 50 day moving average of $77.23 and a 200-day moving average of $82.77. Haemonetics Co. has a 12 month low of $70.25 and a 12 month high of $97.97. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.03. The business had revenue of $345.50 million for the quarter, compared to analysts' expectations of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business's revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.99 EPS. As a group, equities analysts expect that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on HAE shares. CL King started coverage on shares of Haemonetics in a research note on Friday, September 13th. They issued a "buy" rating and a $116.00 target price on the stock. Needham & Company LLC reissued a "buy" rating and set a $112.00 price objective on shares of Haemonetics in a report on Friday. Barrington Research restated an "outperform" rating and issued a $108.00 target price on shares of Haemonetics in a research note on Friday, November 8th. Raymond James upgraded Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price target for the company in a research note on Friday, November 8th. Finally, Bank of America started coverage on Haemonetics in a research note on Wednesday, September 11th. They issued a "neutral" rating and a $85.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $107.88.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.